China Transmucosal Drug Delivery Systems Market to Reach US$ 24,518.6 Mn at a CAGR of 11.2% in 2027 | The Insight Partners

China Transmucosal Drug Delivery Systems Market to 2027 - Regional Analysis and Forecasts by Route of Administration (Oral, Vaginal, Nasal, Urethral/Rectal); Age Group (Adults, Pediatrics); End User (Hospitals, Clinics, Others)

Publication Month: Sep 2019 | Report Code: TIPRE00006570 | No. of Pages: 70 | Category: Medical Device | Status: Published

The China transmucosal drug delivery systems market is expected to reach US$ 24,518.6 Mn in 2027 from US$ 9,520.3 Mn in 2018. The market is estimated to grow with a CAGR of 11.2% from 2019-2027.

 

Rising prevalence of various chronic diseases such as respiratory, gastrointestinal, and autoimmune diseases are expected to surge the market growth. Moreover, the advantages offered by transmucosal route of administration increasing its adaptability is also responsible for boosting the market growth over the years. However, high cost of production of drug delivery devices under stringent regulatory observation is likely to have a negative impact on the growth of the market in the coming years.

 

The development of alternative methods for drug administration has improved the ability of physicians to manage various medical obstacles. One of the promising alternative to traditional drug delivery techniques is the transmucosal route. Drug absorption through a mucosal surface is generally efficient as the major absorption barrier across the skin known as stratum corneum epidermidis is absent in the mucous layers. These surfaces thus are abundant in blood supply thereby facilitating rapid drug transport to the systemic circulation and avoiding the degradation by first-pass hepatic metabolism. Oro-mucosal delivery, especially that utilizing the buccal and sublingual mucosa as absorption site, is a promising drug delivery route which promotes rapid absorption and high bioavailability, with subsequent almost immediate onset of pharmacological effect. Moreover, the patients are feasibly able to control the period of drug administration and terminate the same in case of emergencies through transmucosal routes. Moreover, the drug administration through these routes also avoid harsh enzymes and acids that are encountered during digestion. In addition, the use of this route for drug delivery does not require a technical equipment and can be easily used by a common person making it feasible and a preferred choice. Hence, the collaborative advantages offered by transmucosal route of drug delivery is expected to drive the growth of the market in the coming years.

 

China transmucosal drug delivery systems market, based on route of administration was segmented into oral, vaginal, nasal, and urethral. In 2018, the oral segment held the largest share of the market, by route of administration. Moreover, the oral segment is also anticipated to grow at the highest rate during the forecast period as it is the most preferred and successfully investigated route of administration.

 

 

CHINA TRANSMUCOSAL DRUG DELIVERY SYSTEMS – MARKET SEGMENTATION

By Route of Administration

  • Oral
  • Vaginal
  • Nasal
  • Urethral/Rectal


By Age Group

  • Adults
  • Pediatrics


By
End User

  • Hospitals
  • Clinics
  • Others

 

Companies Mentioned

  • 3M
  • Acrux Limited
  • GW Pharmaceuticals plc
  • INTELGENX CORP
  • Mylan N.V.
  • Novartis AG
  • Reckitt Benckiser Group plc.
  • Teva Pharmaceutical Industries Ltd
  • UCB S.A.
  • West Pharmaceutical Development, LLC

1.             Introduction

1.1       Scope of the Study

1.2       The Insight Partners Research Report Guidance

1.3       Market Segmentation

2.             China Transmucosal Drug Delivery Systems Market – Key Takeaways

3.             Research Methodology

3.1       Coverage

3.2       Secondary Research

3.3       Primary Research

4.             China Transmucosal Drug Delivery Systems Market – Market Landscape

4.1       Overview

4.2       PEST Analysis

4.2.1       China PEST Analysis

4.3       Expert Opinions

4.4       Epidemiology Data

4.5       Regulatory Scenario for Methotryxate in China

4.6       Pricing Analysis

5.             Transmucosal Drug Delivery Systems Market – Key Industry Dynamics

5.1       Key Market Drivers

5.1.1       Rising Prevalence of Chronic Diseases

5.1.2       Advantages of Transmucosal Drug Delivery

5.2       Key Market Restraint

5.2.1       High Cost Involved in the Development of Drug Delivery Devices

5.3       Key Market Opportunity

5.3.1       Increasing Preference Towards Self-Administration and Home Care

5.4       Future Trend

5.4.1       Research and Development in Transmucosal Drug Delivery

5.5       Impact Analysis

6.             China Transmucosal Drug Delivery Systems Market – China Market Analysis

6.1       Overview

6.2       China Transmucosal Drug Delivery Systems Market – Revenue Forecasts and Analysis – 2018- 2027

7.             China Transmucosal Drug Delivery Systems Market Analysis– by Route of Administration

7.1       Overview

7.2       China Transmucosal Drug Delivery Systems Market, By Route of Administration 2018 & 2027 (%)

7.3       Oral Market

7.3.1       Overview

7.3.2       China Oral Market Revenue and Forecasts to 2027 (US$ Mn)

7.4       Vaginal Market

7.4.1       Overview

7.4.2       China Vaginal Market Revenue and Forecasts to 2027 (US$ Mn)

7.5       Nasal Market

7.5.1       Overview

7.5.2       China Nasal Market Revenue and Forecasts to 2027 (US$ Mn)

7.6       Urethral/Rectal Market

7.6.1       Overview

7.6.2       China Urethral/Rectal Market Revenue and Forecasts to 2027 (US$ Mn)

8.             China Transmucosal Drug Delivery Systems Market Analysis– by Age Group

8.1       Overview

8.2       China Transmucosal Drug Delivery Systems Market, By Age Group 2018 & 2027 (%)

8.3       Adults Market

8.3.1       Overview

8.3.2       China Adults Market Revenue and Forecasts to 2027 (US$ Mn)

8.4       Pediatrics Market

8.4.1       Overview

8.4.2       China Pediatrics Market Revenue and Forecasts to 2027 (US$ Mn)

9.             China Transmucosal Drug Delivery Systems Market Analysis– by End User

9.1.1       Overview

9.1.2       China Transmucosal Drug Delivery Systems Market, By End User 2018 & 2027 (%)

9.1.3       Hospitals Market

9.1.4       Overview

9.1.5       China Hospitals Market Revenue and Forecasts to 2027 (US$ Mn)

9.1.6       Clinics Market

9.1.6.1    Overview

9.1.6.2    China Clinics Market Revenue and Forecasts to 2027 (US$ Mn)

9.1.7       Others Market

9.1.7.1    Overview

9.1.7.2    China Others Market Revenue and Forecasts to 2027 (US$ Mn)

10.          Transmucosal Drug Delivery Systems Market – Industry Landscape

10.1    Overview

10.2    Growth Strategies done by the companies in the Market, (%)

10.3    Organic Developments

10.3.1    Overview

10.4    Inorganic developments

10.4.1    Overview

11.          Transmucosal Drug Delivery Systems Market–Key Company Profiles

11.1    3M

11.1.1    Key Facts

11.1.2    Business Description

11.1.3    Financial Overview

11.1.4    Product Portfolio

11.1.5    SWOT Analysis

11.1.6    Key Developments

11.2   Acrux Limited

11.2.1    Key Facts

11.2.2    Business Description

11.2.3    Products and Services

11.2.4    Financial Overview

11.2.5    SWOT Analysis

11.2.6    Key Developments

11.3    GW Pharmaceuticals plc.

11.3.1    Key Facts

11.3.2    Business Description

11.3.3    Financial Information

11.3.4    Product Portfolio

11.3.5    SWOT Analysis

11.3.6    Key Developments

11.4    INTELGENX CORP

11.4.1    Key Facts

11.4.2    Business Description

11.4.3    Financial Information

11.4.4    Product Portfolio

11.4.5    SWOT Analysis

11.4.6    Key Developments

11.5    Mylan N.V.

11.5.1    Key Facts

11.5.2    Business Description

11.5.3    Products and Services

11.5.4    Financial Overview

11.5.5    SWOT Analysis

11.5.6    Key Developments

11.6    Novartis AG

11.6.1    Key Facts

11.6.2    Business Description

11.6.3    Financial Information

11.6.4    Product Portfolio

11.6.5    SWOT Analysis

11.6.6    Key Developments

11.7    Reckitt Benckiser Group plc.

11.7.1    Key Facts

11.7.2    Business Description

11.7.3    Financial Overview

11.7.4    Product Portfolio

11.7.5    SWOT Analysis

11.7.6    Key Developments

11.8    Teva Pharmaceutical Industries Ltd

11.8.1    Key Facts

11.8.2    Business Description

11.8.3    Financial Overview

11.8.4    Product Portfolio

11.8.5    SWOT Analysis

11.8.6    Key Developments

11.9    UCB S.A.

11.9.1    Key Facts

11.9.2    Business Description

11.9.3    Products and Services

11.9.4    Financial Overview

11.9.5    SWOT Analysis

11.9.6    Key Developments

11.10  West Pharmaceutical Services, Inc.

11.10.1 Key Facts

11.10.2 Business Description

11.10.3 Financial Overview

11.10.4 Product Portfolio

11.10.5 SWOT Analysis

11.10.6 Key Developments

12.          Appendix

12.1    About The Insight Partners

12.2    Glossary of Terms


LIST OF TABLES

Table 1.            Number of new cases in China (2018)

Table 2.            Prevalence of Comorbidities in China

Table 3.            Organic Developments Done By Companies

Table 4.            Inorganic developments done by Companies

Table 5.            Glossary of Terms, Transmucosal Drug Delivery Systems Market


LIST OF FIGURES

Figure 1.          Transmucosal Drug Delivery Systems Market Segmentation

Figure 2.          China Transmucosal Drug Delivery Systems Market Overview

Figure 3.          Oral Segment Held Largest Share Of The Route of Administration Segment In Transmucosal Drug Delivery Systems Market

Figure 4.          China Transmucosal Drug Delivery Systems Market, Industry Landscape

Figure 5.          China PEST Analysis

Figure 6.          Number of new cases China (2018)

Figure 7.          Impact Analysis of Drivers and Restraint Pertaining to Transmucosal Drug Delivery Systems Market

Figure 8.          China Transmucosal Drug Delivery Systems Market – Revenue Forecasts and Analysis – 2018- 2027

Figure 9.          China Transmucosal Drug Delivery Systems Market, by Route of Administration 2018 & 2027 (%)

Figure 10.       China Oral Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 11.       China Vaginal Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 12.       China Nasal Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 13.       China Urethral/Rectal Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 14.       China Transmucosal Drug Delivery Systems Market, by Age Group 2018 & 2027 (%)

Figure 15.       China Adults Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 16.       China Pediatrics Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 17.       China Transmucosal Drug Delivery Systems Market, by End User 2018 & 2027 (%)

Figure 18.       China Hospitals Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 19.       China Clinics Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 20.       China Others Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 21.       Growth Strategies done by the companies in the Market, (%)

 

The List of Companies

  1. 3M
  2. Acrux Limited
  3. GW Pharmaceuticals plc
  4. INTELGENX CORP
  5. Mylan N.V.
  6. Novartis AG
  7. Reckitt Benckiser Group plc.
  8. Teva Pharmaceutical Industries Ltd
  9. UCB S.A.
  10. West Pharmaceutical Development, LLC